STAT+: FDA ‘uncertainty’ forces Krystal Biotech to shutter cancer drug trial
Written by
STAT News
Published
0
comments
0
min
The FDA's controversial rejection of a skin cancer therapy from Replimune Group has prompted Krystal Biotech to shut down of a clinical trial involving a similar drug.